NCT07145489 Infrared Photobiomodulation in Humans With Epilepsy
| NCT ID | NCT07145489 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Beth Israel Deaconess Medical Center |
| Condition | Drug Resistant Epilepsy |
| Study Type | INTERVENTIONAL |
| Enrollment | 13 participants |
| Start Date | 2025-11-25 |
| Primary Completion | 2026-09-25 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 13 participants in total. It began in 2025-11-25 with a primary completion date of 2026-09-25.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Drug-resistant epilepsy represents roughly 40% of people with epilepsy. It is very challenging to stop seizures in this condition, and the treatment options are limited. This study aims to investigate a new treatment that involves using infra-red light. In animals, this treatment has shown promise as a possible way to reduce seizures, but it has not been tested in humans for this. The investigators are interested to know if it can reduce seizures, and how comfortable it is to be treated with this therapy.
Eligibility Criteria
Inclusion Criteria: * Drug resistant epilepsy * Age 18 or older * Average seizure rate of at least 2 seizures per month * Accurate seizure diary with at least 3 months recorded Exclusion Criteria: * Implanted intracranial neurostimulation device (DBS or RNS) * Intracranial shunt * Skin photosensitivity * Cancer on scalp * Taking any medication that can cause photosensitivity
Contact & Investigator
Daniel Goldenholz, MD PhD
PRINCIPAL INVESTIGATOR
Beth Israel Deaconess Medical Center
Frequently Asked Questions
Who can join the NCT07145489 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Drug Resistant Epilepsy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07145489 currently recruiting?
Yes, NCT07145489 is actively recruiting participants. Contact the research team at daniel.goldenholz@bidmc.harvard.edu for enrollment information.
Where is the NCT07145489 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT07145489 clinical trial?
NCT07145489 is sponsored by Beth Israel Deaconess Medical Center. The principal investigator is Daniel Goldenholz, MD PhD at Beth Israel Deaconess Medical Center. The trial plans to enroll 13 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.